ArticleESMO open2022

A first-in-human study of the anti-LAG-3 antibody favezelimab plus pembrolizumab in previously treated, advanced microsatellite stable colorectal cancer.

E Garralda et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.